COMBINATIONS FOR THE TREATMENT OF B-CELL PROLIFERATIVE DISORDERS

• US 20090047243A1
• Filed: 07/17/2008
• Published: 02/19/2009
• Est. Priority Date: 07/17/2007
• Status: Abandoned Application

• Current Assignee: Zalicus Inc. (EPIRUS Biopharmaceuticals, Inc.)
• Original Assignee: Zalicus Inc. (EPIRUS Biopharmaceuticals, Inc.)
• Inventors: Rickles, Richard, Pierce, Laura, Lee, Margaret S.
• Application Number:
  US12/175,121
• Publication Number:
  US 20090047243A1
• Time in Patent Office: Days
• US Class Current: 424/85.200
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/00 Medicinal preparations containing organic active ingredients
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61P 35/00 Antineoplastic agents

Abstract

The invention features compositions and methods employing combinations of an A2A receptor agonist and a PDE inhibitor for the treatment of a B-cell proliferative disorder, e.g., multiple myeloma.

Claims

1. A method of treating a B-cell proliferative disorder, said method comprising administering to a patient a combination of an A2A receptor agonist and a PDE inhibitor in amounts that together are effective to treat said B-cell proliferative disorder.

2. The method of claim 1, wherein said A2A receptor agonist is selected from the group consisting of the compounds listed in Tables 1 and 2.

3. The method of claim 1, wherein said PDE inhibitor is selected from the group consisting of the compounds listed in Tables 3 and 4.

4. The method of claim 1, wherein said PDE inhibitor is active against at least two of PDE 2, 3, 4, and 7.

5. The method of claim 1, wherein said combination comprises two or more PDE inhibitors that when combined are active against at least two of PDE 2, 3, 4, and 7.

6. The method of claim 1, wherein said B-cell proliferative disorder is selected from the group consisting of autoimmune lymphoproliferative disease, B-cell CLL, B-cell prolymphocyte leukemia, lymphoplasmacytic lymphoma, mantle cell lymphoma, follicular lymphoma, extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT type), nodal marginal zone lymphoma, splenic marginal zone lymphoma, hairy cell leukemia, plasmacytoma, diffuse large B-cell lymphoma, Burkitt lymphoma, multiple myeloma, indolent myeloma, smoldering myeloma, monoclonal gammopathy of unlcnown significance (MGUS), B-cell non-Hodgkin'"'"'s lymphoma, small lymphocytic lymphoma, monoclonal immunoglobin deposition diseases, heavy chain diseases, mediastinal (thymic) large B-cell lymphoma, intravascular large B-cell lymphoma, primary effusion lymphoma, lymphomatoid granulomatosis, precursor B-lymphoblastic leukemia/lymphoma, Hodgkin'"'"'s lymphoma, nodular lymphocyte predominant Hodgkin'"'"'s lymphoma, classical Hodgkin'"'"'s lymphoma, nodular sclerosis Hodgkin'"'"'s lymphoma, mixed cellularity Hodgkin'"'"'s lymphoma, lymphocyte-rich classical Hodgkin'"'"'s lymphoma, lymphocyte depleted Hodgkin'"'"'s lymphoma, post-transplant lymphoproliferative disorder, and Waldenstrom'"'"'s macroglobulineamia.

7. The method of claim 1, wherein said B-cell proliferative disorder is multiple myeloma.

8. The method of claim 1, wherein said A2A receptor agonist and PDE inhibitor are administered simultaneously.

9. The method of claim 1, wherein said A2A receptor agonist and PDE inhibitor are administered within 14 days of one another.

10. The method of claim 1, wherein said patient is not suffering from a comorbid immunoinflammatory disorder.

11. The method of claim 1, further comprising administering an antiproliferative compound.

12. The method of claim 11, wherein said antiproliferative compound is selected from the group consisting of alkylating agents, platinum agents, antimetabolites, topoisomerase inhibitors, antitumor antibiotics, antimitotic agents, aromatase inhibitors, thymidylate synthase inhibitors, DNA antagonists, farnesyltransferase inhibitors, pump inhibitors, histone acetyltransferase inhibitors, metalloproteinase inhibitors, ribonucleoside reductase inhibitors, TNF alpha agonists/antagonists, endothelin A receptor antagonist, retinoic acid receptor agonists, immuno-modulators, hormonal and antihormonal agents, photodynamic agents, tyrosine kinase inhibitors, antisense compounds, corticosteroids, HSP90 inhibitors, proteosome inhibitors, CD40 inhibitors, anti-CSI antibodies, FGFR3 inhibitors, VEGF inhibitors, MEK inhibitors, cyclin D1 inhibitors, NF-kB inhibitors, anthracyclines, histone deacetylases, kinesin inhibitors, phosphatase inhibitors, COX2 inhibitors, mTOR inhibitors, calcineurin antagonists, and IMiDs.

13. The method of claim 11, wherein said antiproliferative compound is selected from the compounds listed in Tables 5 and 6.

14. The method of claim 1, further comprising administering a combination of at least two antiproliferative compounds.

15. The method of claim 14, wherein said combination is selected from the group consisting of CHOP (cyclophosphamide, vincristine, doxorubicin, and prednisone), VAD (vincristine, doxorubicin, and dexamethasone), MP (melphalan and prednisone), DT (dexamethasone and thalidomide), DM (dexamethasone and melphalan), DR (dexamethasone and Revlimid), DV (dexamethasone and Velcade), RV (Revlimid and Velcade), and cyclophosphamide and etoposide.

16. The method of claim 1, further comprising administering IL-6, a compound that increases IL-6 expression, or an IL-6 receptor agonist to said patient.

17. The method of claim 1, wherein said PDE inhibitor is active against PDE 4.

18. A kit comprising (i) a PDE inhibitor and (ii) an A2A receptor agonist in an amount effective to treat a B-cell proliferative disorder.

22. The kit of claim 18-20, further comprising an antiproliferative compound.

19. A kit comprising (i) an A2A receptor agonist and (ii) a PDE inhibitor having activity against at least two of PDE 2, 3, 4, and 7.

20. A kit comprising (i) an A2A receptor agonist and (ii) two or more PDE inhibitors that when combined have activity against at least two of PDE 2, 3, 4, and 7.

21. A kit comprising (i) an A2A receptor agonist, (ii) a PDE inhibitor, and (iii) an antiproliferative compound.

23. The kit of claim 21-22, wherein said antiproliferative compound is selected from the group consisting of alkylating agents, platinum agents, antimetabolites, topoisomerase inhibitors, antitumor antibiotics, antimitotic agents, aromatase inhibitors, thymidylate synthase inhibitors, DNA antagonists, farnesyltransferase inhibitors, pump inhibitors, histone acetyltransferase inhibitors, metalloproteinase inhibitors, ribonucleoside reductase inhibitors, TNF alpha agonists/antagonists, endothelin A receptor antagonist, retinoic acid receptor agonists, immuno-modulators, hormonal and antihormonal agents, photodynamic agents, tyrosine kinase inhibitors, antisense compounds, corticosteroids, HSP90 inhibitors, proteosome inhibitors, CD40 inhibitors, anti-CSI antibodies, FGFR3 inhibitors, VEGF inhibitors, MEK inhibitors, cyclin D1 inhibitors, NF-kB inhibitors, anthracyclines, histone deacetylases, kinesin inhibitors, phosphatase inhibitors, COX2 inhibitors, mTOR inhibitors, calcineurin antagonists, and IMiDs.

24. The kit of claims 21-22, further comprising at least a second antiproliferative compound in a combination with said antiproliferative compound.

25. The kit of claim 24, wherein said combination is selected from the group consisting of CHOP (cyclophosphamide, vincristine, doxorubicin, and prednisone), VAD (vincristine, doxorubicin, and dexamethasone), MP (melphalan and prednisone), DT (dexamethasone and thalidomide), DM (dexamethasone and melphalan), DR (dexamethasone and Revlimid), DV (dexamethasone and Velcade), RV (Revlimid and Velcade), and cyclophosphamide and etoposide.

26. A pharmaceutical composition comprising (i) a PDE inhibitor and (ii) an A2A receptor agonist in an amount effective to treat a B-cell proliferative disorder and (iii) a pharmaceutically acceptable carrier.

27. A pharmaceutical composition comprising (i) an A2A receptor agonist and (ii) a PDE inhibitor having activity against at least two of PDE 2, 3, 4, and 7 and (iii) a pharmaceutically acceptable carrier.

28. A pharmaceutical composition comprising (i) an A2A receptor agonist and (ii) two or more PDE inhibitors that when combined have activity against at least two of PDE 2, 3, 4, and 7 and (iii) a pharmaceutically acceptable carrier.

29. A kit comprising:

(i) a composition comprising an A2A receptor agonist and a PDE inhibitor; and

(ii) instructions for administering said composition to a patient for the treatment of a B-cell proliferative disorder.

33. The kit of any of claims 29-32, wherein said PDE inhibitor has activity against at least two of PDE 2, 3, 4, and 7.

30. A kit comprising:

(i) an A2A receptor agonist; and

(ii) instructions for administering said A2A receptor agonist with a PDE inhibitor to a patient for the treatment of a B-cell proliferative disorder.

31. A kit comprising:

(i) a PDE inhibitor; and

(ii) instructions for administering said PDE inhibitor with an A2A receptor agonist to a patient for the treatment of a B-cell proliferative disorder.

32. A kit comprising:

(i) a PDE inhibitor;

(ii) an A2A receptor agonist; and

(iii) instructions for administering said PDE inhibitor and said A2A receptor agonist to a patient for the treatment of a B-cell proliferative disorder.

34. A kit comprising:

(i) two or more PDE inhibitors that when combined have activity against at least two of PDE2, 3, 4, and 7;

(ii) an A2A receptor agonist; and

(iii) instructions for administering said two or more PDE inhibitors and said A2A receptor agonist to a patient for the treatment of a B-cell proliferative disorder.